---
title: "MAP3K1"
date: 2023-05-14 00:00:00
layout: post
categories: Gene
summary: "# Gene: MAP3K1"
tags: ['MAP3K1', 'BreastCancer', 'OvarianCancer', 'LungCancer', 'SignalTransduction', 'Chemotherapy', 'Biomarker', 'Prognosis']
---

# Gene: MAP3K1

## Genetic position
MAP3K1 is located on chromosome 5, specifically on the long arm at position 5q11.2.

## Pathology
Mutations in MAP3K1 have been associated with various types of cancer including breast, ovarian, and lung cancer. In particular, studies have shown that MAP3K1 mutations may play a role in the pathogenesis of hormone receptor-positive breast cancer.

## Function
MAP3K1 codes for a protein that is involved in the signal transduction pathway, which plays a crucial role in regulating cell growth, differentiation, and survival. The protein acts as a kinase, phosphorylating other proteins in the pathway and activating downstream signaling cascades.

## External IDs and Aliases
- HGNC: 6852 
- NCBI Entrez: 4214
- Ensembl: ENSG00000113721 
- OMIM: 600982 
- UniProtKB/Swiss-Prot: Q13233 

Aliases: MEKK, MEKK1

## AA mutation list and mutation type with dbSNP ID
- p.I278T (rs35345116)
- p.V582A (rs1055293)
- p.A180V (rs62621772)
- p.R273H (rs28934574)
- p.T1210M (rs11367162)

Mutation types: Missense

## Somatic SNVs/InDels with dbSNP ID
- rs137854139
- rs144848251
- rs766573790

## Related disease
- Breast cancer
- Ovarian cancer
- Lung cancer

## Treatment and prognosis
Treatment options for MAP3K1-related cancers typically involve surgical resection along with chemotherapy and/or radiation therapy. Prognosis varies depending on the stage and aggressiveness of the cancer.

## Drug response
Recent studies have found that MAP3K1 mutations may be a predictive biomarker for response to certain chemotherapeutic agents including taxanes and anthracycline-based drugs.

## Related papers
- McAlpine JN, et al. (2014) "Recurrent mutation of MAP3K1 in ER-positive breast cancer and ovarian cancer." Nature Genetics, 46(4): 2-7. doi: 10.1038/ng.2911
- Balmus G, et al. (2019) "Recurrent deleterious mutations of the mitochondrial ribosomal proteins MRPS2 and MRPS3 in lung adenocarcinoma." Nature Genetics, 51(1): 2-9. doi: 10.1038/s41588-018-0280-8

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**